For the quarter ending 2025-06-30, TSBX made $251K in revenue. -$5,490K in net income. Net profit margin of -2187.25%.
| Income Statement | 2025-06-30 | 2024-12-31 | 2024-09-30 | |
|---|---|---|---|---|
| Research and development | - | 13,893 | 14,424 | |
| General and administrative | - | 4,149 | 3,944 | |
| Total operating expenses | - | 18,042 | 18,368 | |
| Loss from operations | - | -18,042 | -18,368 | |
| Other income, net | - | 391 | 520 | |
| Net loss before income taxes | - | -17,651 | -17,848 | |
| Other segment expense | 218 | - | - | |
| Research and development-TIDAL-01 | -48 | - | - | |
| Research and development-Compensation | 406 | - | - | |
| Other income, net | 81 | - | - | |
| Provision for income taxes | 12 | - | - | |
| General and administrative | 5,388 | - | - | |
| Benefit (provision) for income taxes | - | 284 | -816 | |
| Depreciation expense | 31 | - | - | |
| Net loss | -5,490 | -17,935 | -17,032 | |
| Oci, debt securities, available-for-sale, gain (loss), before adjustment, after tax, total | - | - | 30 | |
| Net loss attributable to common stockholders, basic | - | -17,709 | - | |
| Comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest | - | - | -17,002 | |
| Net loss attributable to common stockholders, diluted | - | -17,709 | - | |
| Earnings per share, basic | -0.24 | -0.777 | -0.74 | |
| Earnings per share, diluted | -0.24 | -0.777 | -0.74 | |
| Weighted-average number of basic shares used in computing net earnings (loss) per share | 23,140,510 | -212 | 23,037,714 | |
| Weighted-average number of diluted shares used in computing net earnings (loss) per share | 23,140,510 | -212 | 23,037,714 | |
Turnstone Biologics Corp. (TSBX)
Turnstone Biologics Corp. (TSBX)